NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Core Insights - NeuraClick, Inc. has appointed Daniel M. Bradbury as Strategic and Metabolic Programs Advisor, bringing over 40 years of leadership experience in the life sciences industry [1][2] Company Overview - NeuraClick, Inc. is a privately held, preclinical-stage biopharmaceutical company focused on developing novel neurotherapeutics using proprietary click chemistry technology applied to naturally occurring peptides [3] - The company aims to create safer, more potent drugs that are easy to administer, long-acting, and free from major side effects [3] - NeuraClick's lead programs target critical unmet needs in major depression, addiction, and obesity, with potential applications for other complex diseases globally [3] Leadership and Expertise - Daniel M. Bradbury's experience includes guiding global biopharmaceutical businesses and advancing novel medicines to market [2] - He is the Executive Chairman and Co-Founder of Equillium, Inc. and previously served as CEO of Amylin Pharmaceuticals, leading the company through significant expansion and its acquisition by Bristol Myers Squibb [2]